The Plan B One-Step tablet contains 1.5 mg of a single active steroid ingredient, levonorgestrel, a totally synthetic progestogen.
Plan B ® One-Step is a progestin-only emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. To obtain optimal efficacy, the tablet should be taken as soon as possible within 72 hours of intercourse.
Plan B One-Step is available only by prescription for women younger than age 17 years, and available over the counter for women 17 years and older.
Plan B One-Step is not indicated for routine use as a contraceptive.
Media Articles Related to Plan B One-Step (Levonorgestrel)
Male contraceptive proves effective as alternative to vasectomy
Source: Pregnancy / Obstetrics News From Medical News Today [2017.02.07]
A new trial in adult rhesus monkeys tests the effectiveness of Vasalgel - a non-hormonal gel developed as a long-term form of male contraception.
Published Studies Related to Plan B One-Step (Levonorgestrel)
Short-Term Treatment of Bothersome Bleeding for Etonogestrel Implant Users Using
a 14-Day Oral Contraceptive Pill Regimen: A Randomized Controlled Trial. 
during a 14-day course... CONCLUSION: Bothersome bleeding in etonogestrel contraceptive implant users will
An overview of four studies of a continuous oral contraceptive (levonorgestrel 90
mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual
and premenstrual syndrome (PMS)... CONCLUSIONS: These data, although not consistent, indicate that continuous LNG/EE
Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trial. [2011.11.29]
BACKGROUND: This study evaluated the ethinyl estradiol (EE) and levonorgestrel (LNG) pharmacokinetic profiles of AG200-15, a transdermal contraceptive delivery system, compared with a combination oral contraceptive (COC) containing EE 35 mcg and norgestimate 250 mcg... CONCLUSIONS: EE and LNG daily exposure during AG200-15 treatment was within the range reported for a low-dose COC. The daily EE dose with AG 200-15 was equivalent to a 30-mcg COC and was safe and well tolerated. Copyright (c) 2011 Elsevier Inc. All rights reserved.
Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial. [2011.09.24]
OBJECTIVE: The purpose of this study was to evaluate whether oral naproxen or transdermal estradiol decreases bleeding and spotting in women who are initiating the levonorgestrel-releasing intrauterine system... CONCLUSION: The administration of naproxen resulted in a reduction in bleeding and spotting days compared with placebo. Copyright A(c) 2011 Mosby, Inc. All rights reserved.
Immediate versus delayed insertion of the levonorgestrel-releasing intrauterine device following dilation and evacuation: a randomized controlled trial. [2011.09.13]
BACKGROUND: The study was conducted to compare 6-month usage of the levonorgestrel-releasing intrauterine device (LNG-IUD) when placed immediately or 3 to 6 weeks after dilation and evacuation (D&E) procedure... CONCLUSION: Significantly more participants had the LNG-IUD placed in the immediate insertion group compared with the delayed insertion group. Given the low risk of complications, immediate post-D&E insertion of the LNG-IUD should be offered, especially for populations that may have difficulty returning for follow-up. Copyright (c) 2011 Elsevier Inc. All rights reserved.
Clinical Trials Related to Plan B One-Step (Levonorgestrel)
Written Asthma Actions Plans Versus No Written Instructions In Specialty Care [Completed]
The overall goal of this randomized, controlled study is to compare a model written
treatment plan with the usual care that is provided by a group of adult and pediatric
pulmonologists and allergists in their practice settings. The written treatment plan is a
form that allows a treatment regimen that is consistent with National Heart, Lung, and Blood
Institute (NHLBI) guidelines to be conveyed to patients. Barriers to the use of written
plans will be identified to better understand why some patients and physicians use written
treatment plans more frequently and effectively than others. An additional goal is to assess
how patients from different racial/ethnic backgrounds utilize treatments plans. Because
asthma disproportionately affects African American and Latino patients, another goal of this
study is to better understand if there are fundamental differences in the way patients from
racial/ethnic minority groups self-manage asthma in comparison to their white counterparts.
The study will also try to determine if differences exist in the way physicians care for
minority patients. If there are differences, it is important to determine if the disparities
can be overcome with the use of a written treatment plan form.
Wellness Action Plan Trial Addressing Childhood Obesity [Completed]
The objective of this study was to determine the effectiveness of a novel Wellness Action
Plan aimed at 1) improving parent recall of diet and activity plans 2) increasing
follow-through with plans and 3) aiding parents in identifying their child's weight
Patient and Provider Initiated Survivorship Care Planning [Recruiting]
Objective: to describe and compare the implementation of two cancer survivorship care tools:
(1) 'My Care Plan': a patient-initiated tool and (2) 'Survivorship Care Plan Builder': a
provider-initiated tool. The results of this study will be used to (1) provide an initial
assessment of the two survivorship care planning tools and (2) inform the design and conduct
of a larger study.
Comparing Asthma Action Plans for Pediatric Asthma [Terminated]
The purpose of this study is to evaluate and compare the relative effectiveness of two
asthma action plans (pictorial versus written) in terms of asthma action plan knowledge,
medication use, and family satisfaction with asthma education.
Study of Survivorship Care Plans and Outcomes in Underserved Breast Cancer Survivors [Active, not recruiting]
Improvements in early detection and successful treatment of breast cancer have lead to a
steady rise in the number of breast cancer (BC) survivors. With so many individuals living
for extended periods after diagnosis, the Institute of Medicine (IOM) recommends the
implementation of treatment summaries and survivorship care plans (TSSPs) as a mechanism to
improve ongoing clinical and coordination of care, and to address the immediate
post-treatment and long-term effects of cancer treatment, including the ongoing psychosocial
burden of a cancer diagnosis. The need for TSSPs has also been strongly advocated by the
American Society of Clinical Oncology's Quality Oncology Practice Initiative and TSSPs have
been included in the recently introduced Comprehensive Cancer Improvement Act (H. R. 1844).
This will be one of the first randomized controlled trials to test the efficacy of TSSPs.
The investigators will recruit 500 low income, medically underserved women from two county
public hospitals, LAC+USC Medical Center and Harbor-UCLA Medical Center, 10-24 months after
breast cancer diagnosis for participation in a randomized controlled trial (RCT) designed to
test the efficacy of TSSPs. The investigators will randomize these women into one of two
groups: 1) a control condition of usual medical care and 2) an experimental condition of the
control condition + a tailored TSSP + 1 face-to-face nurse counseling session, with all
cancer specialists and primary care physicians of record also receiving the TSSP and a cover
letter suggesting how they can be clinically utilized.
The investigators specific aims are to assess and compare between experimental and control
groups the following primary outcomes at one year post-intervention: 1) discussion and
implementation of recommended breast cancer survivorship care, including surveillance and
the evaluation and management of BC treatment-related symptoms, 2) patient satisfaction with
survivorship communication and care, 3) pertinent aspects of health-related quality of life,
and further, to then 4) assess the cost-consequences of the experimental intervention. This
study will provide a unique opportunity to assess the efficacy of TSSPs in a low-income,
underserved population of BC survivors known to be at high risk for poorer long-term
outcomes, including in mental health, quality of life, recurrence and mortality, and will
therefore allow us to demonstrate the greatest possible benefit of such an intervention.
Reports of Suspected Plan B One-Step (Levonorgestrel) Side Effects
Menstruation Irregular (3534),
Pelvic Pain (665),
Menstruation Delayed (446),
Abdominal Pain (289),
Breast Tenderness (216), more >>
Page last updated: 2017-02-07